Analyst Price Target is $54.00
▲ +43.85% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Pro Medicus in the last 3 months. The average price target is $54.00, with a high forecast of $54.00 and a low forecast of $54.00. The average price target represents a 43.85% upside from the last price of $37.54.
Current Consensus is
Hold
The current consensus among 3 contributing investment analysts is to hold stock in Pro Medicus. This rating has held steady since January 2021, when it changed from a Buy consensus rating.
Pro Medicus Limited develops and supplies healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. It provides Radiology Information Systems (RIS) proprietary medical software for practice management. The company also offers Healthcare imaging software that provides radiologists and clinicians with visualization capability for viewing 2-D, 3-D, and 4-D medical images, as well as picture archive and communication system (PACS)/digital imaging software; Promedicus.net., an e-health platform; and integration products. In addition, it offers Visage Ease Pro, a mobile application, which allow users to interpret medical imaging studies that are stored on a Visage 7 server; training, installation, and professional services; and after sale support and service products. The company provides its products under the Visage RIS, Visage RIS/PACS, Visage 7, and Visage Ease names. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.
Read More